Issue 135 • October 2023
How pharma wants to break the efficacy ceiling in IBD
Despite major shifts in the inflammatory bowel disease landscape, most novel approaches remain in the earlier stages of development
In association with
Issue 135 • October 2023
Despite major shifts in the inflammatory bowel disease landscape, most novel approaches remain in the earlier stages of development
In association with